Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants
PHASE1
The purpose of this study was to assess the safety and pharmacokinetics (PK...
Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
PHASE1
Background:
The human body uses antibodies as one way to help fight infect...
Status
Completed
Location
University of Alabama HIV Clinic Clinical Research Site, AIDS Clinical Trials Group (ACTG)
VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
PHASE1
Background:
Human immunodeficiency virus (HIV) is a global health threat. ...
Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults
PHASE1
The purpose of this study is to evaluate the safety, tolerability, and seru...